NovaBay Pharmaceuticals, Inc.
NBY · AMEX
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.01 | 0.01 |
| FCF Yield | -88.64% | -42.64% | -33.11% | -76.20% |
| EV / EBITDA | 0.48 | 1.29 | -3.50 | -3.11 |
| Quality | ||||
| ROIC | -35.77% | -45.12% | -2.93% | -45.46% |
| Gross Margin | 0.00% | 0.00% | 65.05% | 65.26% |
| Cash Conversion Ratio | 1.39 | 1.52 | 0.40 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | -39.49% | -29.13% | -19.03% | -10.75% |
| Free Cash Flow Growth | -125.91% | -36.21% | 50.10% | -188.17% |
| Safety | ||||
| Net Debt / EBITDA | 2.23 | 2.24 | -1.04 | -0.50 |
| Interest Coverage | -34.38 | 0.00 | -39.06 | -7.69 |
| Efficiency | ||||
| Inventory Turnover | 0.08 | 0.00 | 1.05 | 1.79 |
| Cash Conversion Cycle | -324.47 | -1,309.09 | 31.00 | 34.13 |